ClinicalTrials.Veeva

Menu

Slow-Paced Breathing and Electrical Vagus Nerve Stimulation as Add-on Treatments for Depression (Add-Vagus)

E

Elisabeth Balint

Status

Not yet enrolling

Conditions

Depression - Major Depressive Disorder

Treatments

Other: Treatment as Usual (TAU)
Device: Transcutaneous Auricular Vagus Nerve Stimulation (tVNS)
Behavioral: Slow-Paced Breathing
Device: Sham Auricular Electrical Stimulation

Study type

Interventional

Funder types

Other

Identifiers

NCT07844733
2026-01402

Details and patient eligibility

About

Depression is a common mental health condition, and standard psychiatric therapies do not always lead to satisfactory recovery. As a result, there is an urgent need for effective, complementary treatments.

The vagus nerve is the main component of the parasympathetic nervous system, which regulates bodily rest and calms inflammatory responses. In clinical depression, vagus nerve activity is often reduced, and low-grade inflammation is frequently observed. While electrical stimulation of the vagus nerve via surgically implanted devices has been shown to reduce depressive symptoms, its invasive nature carries risks. Non-invasive alternatives-such as slow-paced breathing exercises or gentle transcutaneous electrical stimulation at the outer ear-offer promising ways to stimulate this nerve safely without surgery.

The main purpose of this clinical study is to evaluate whether slow-paced breathing is an effective add-on therapy to reduce depressive symptoms in hospitalized patients compared to standard multimodal psychiatric treatment. Additionally, the study investigates whether the effects of slow-paced breathing are comparable to transcutaneous auricular vagus nerve stimulation (tVNS) and whether they differ from a sham (placebo) stimulation.

A total of 160 adult inpatients with at least a moderate depressive episode will be randomly assigned to one of four groups during their hospital stay:

Group 1 (Slow-Paced Breathing): Participants practice a guided, slow-paced breathing technique (inhaling for 4 seconds, exhaling for 6 seconds) for 20 minutes, 3 times daily, 5 days per week over 4 weeks.

Group 2 (Electrical Vagus Nerve Stimulation): Participants receive non-invasive electrical stimulation to the outer ear canal using a certified medical device (tVNS) for 20 minutes, 3 times daily, 5 days per week over 4 weeks.

Group 3 (Sham Stimulation): Participants receive identical-looking electrical stimulation applied to the earlobe (an area lacking vagal nerve fibers) on the same schedule, serving as an active control. Participants do not know whether they receive active or sham stimulation.

Group 4 (Treatment as Usual): Participants receive the standard multimodal inpatient psychiatric treatment program alone, alongside daily logging of relaxation and mindfulness activities.

All participants continue to receive standard psychiatric care. Depressive symptoms are assessed using the Beck Depression Inventory-II (BDI-II) and the Hamilton Depression Rating Scale. In addition, heart rate variability (HRV) via a 24-hour recording and blood inflammatory markers (such as IL-6 and CRP) are measured before and after the 4-week intervention period to explore the physiological mechanisms of vagus activation. A follow-up questionnaire is completed after 3 months to assess long-term outcomes.

Enrollment

160 estimated patients

Sex

All

Ages

18 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Inpatient psychiatric admission at Privatklinik Meiringen
  • Clinical primary diagnosis of at least a moderate depressive episode
  • Beck Depression Inventory-II (BDI-II) score of at least 20 at admission
  • Age between 18 and 60 years
  • Written informed consent prior to study participation
  • Ability to understand the study procedures and give informed consent

Exclusion criteria

  • Active substance use disorder / addiction
  • Current psychosis
  • Bipolar disorder
  • Borderline personality disorder
  • Current malignancy
  • Multiple sclerosis
  • Presence of a cardiac pacemaker
  • Known or confirmed pregnancy
  • Body Mass Index (BMI) greater than 35 kg/m²
  • Current treatment with, or planned administration during the hospital stay of, ketamine or electroconvulsive therapy (ECT)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

160 participants in 4 patient groups

Slow-Paced Breathing
Experimental group
Description:
Participants perform a guided, device-free slow-paced breathing technique with prolonged exhalation (inhalation for 4 seconds, exhalation for 6 seconds) to stimulate the vagus nerve. The intervention is practiced for 20 minutes, 3 times daily (morning, afternoon, evening), on 5 days per week over a period of 4 weeks. Participants sit alone in a room and complete a daily protocol logging session duration, breathing frequency, and side effects. This intervention is administered in addition to standard inpatient psychiatric treatment (Treatment as Usual).
Treatment:
Behavioral: Slow-Paced Breathing
Transcutaneous Auricular Vagus Nerve Stimulation (tVNS)
Active Comparator group
Description:
Participants receive non-invasive transcutaneous electrical stimulation of the auricular branch of the vagus nerve via a CE-certified ear electrode (tVNS device) placed in the cymba conchae of the left ear. Stimulation is applied for 20 minutes, 3 times daily, on 5 days per week over 4 weeks. Stimulation parameters include 25 Hz frequency, 250 µs pulse width, with alternating 28 s ON and 32 s OFF cycles at individually adjusted sensory thresholds (0.1-5.0 mA). Administered as an add-on to standard inpatient psychiatric treatment.
Treatment:
Device: Transcutaneous Auricular Vagus Nerve Stimulation (tVNS)
Sham Auricular Stimulation
Sham Comparator group
Description:
Participants receive identical-looking electrical stimulation applied to the left earlobe, an area free of cutaneous vagal innervation, serving as an active sensory placebo control. The session schedule (20 minutes, 3 times daily, 5 days per week for 4 weeks) and technical stimulus parameters match the active tVNS arm. Participants are blinded regarding whether they receive active or sham stimulation. Administered in addition to standard inpatient psychiatric treatment.
Treatment:
Device: Sham Auricular Electrical Stimulation
Treatment as Usual (TAU)
Other group
Description:
Participants receive the standard multimodal inpatient psychiatric and psychotherapeutic treatment program alone, including medical visits, psychopharmacotherapy, individual and group psychotherapy, and standard ward activities. To mitigate nocebo effects, participants are instructed to engage in standard relaxation/mindfulness elements offered on the ward and keep a daily log of time spent on relaxation exercises. No experimental breathing or electrical nerve stimulation is applied.
Treatment:
Other: Treatment as Usual (TAU)

Trial contacts and locations

1

Loading...

Central trial contact

Elisabeth M Balint, PD Dr. med.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems